SCHEDULE: Nantahala Capital Discloses 9.99% Stake in Unicycive

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in UNICYCIVE THERAPEUTICS, INC. as of December 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively hold a beneficial ownership of 2,281,040 shares of UNICYCIVE THERAPEUTICS, INC. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of the company.
• The reported shares include 1,341,838 shares that can be acquired by the Reporting Persons within sixty days through the exercise of convertible securities.
• Nantahala Capital Management, LLC, as an investment adviser, and Messrs. Harkey and Mack, as control persons, share voting and dispositive power over these shares.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, has the right to receive dividends or proceeds from the sale of more than five percent of the beneficially owned shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a routine regulatory disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative outlook for the company's operational performance or strategic direction.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of UNICYCIVE THERAPEUTICS, INC.
• The acquisition and holding of securities were not in connection with or as a participant in any transaction having the purpose or effect of changing or influencing control, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing is a standard regulatory disclosure indicating a significant passive ownership stake by an institutional investor and its principals in UNICYCIVE THERAPEUTICS, INC. Such filings provide transparency regarding major shareholders but do not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake provides transparency regarding the company's ownership structure, which can influence investor perception and potentially liquidity.

Key Dates

Keywords

UNICYCIVE THERAPEUTICS, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Convertible Securities